Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
Business Wire•03/11/2026•06:45 ET
0
Key Highlights
- ➤2026 third-quarter revenue $16.6 billion, relatively flat operationally year-over-year
- ➤Adjusted diluted EPS $0.87, unchanged year-over-year
- ➤2026 revenue guidance raised $1.5 billion midpoint to $62.0-$64.0 billion
- ➤Adjusted diluted EPS guidance raised and narrowed to $2.95-$3.05
- ➤Launched and acquired products revenue grew 32% operationally year-over-year
Expert Statements
Albert Bourla, Chairman and CEO of Pfizer
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we’re well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
Cecile Guegan, Chief Financial Officer and Executive Vice President of Pfizer
“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products((1)). Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”
Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
* Focused Execution Drove 32% Operational Revenue Growth of Launched and Acquired Products((1))
Get started
Create a free account to read the full story.